Proteome Systems wins technology innovation award
21 July, 2005 by Graeme O'NeillProteome Systems has won a prestigious 2005 Frost and Sullivan Technology Innovation Award for its ingenious Chemical Inkjet Printer (ChIP).
In brief: Pharmaxis, Cochlear, OBJ, Cryptome Pharmaceuticals
21 July, 2005 by Staff WritersOn the back of yesterday's announcement, Pharmaxis (ASX:PXC) has been granted approval from Health Canada to conduct a clinical trial of Bronchitol in patients with cystic fibrosis.
Continence Control Systems starts first human implant recruitment
21 July, 2005 by Ruth BeranBioTech Capital (ASX:BTC) investee company Continence Control Systems International (CCS) has commenced patient recruitment for its severe urinary incontinence treatment, following completion of pre-clinical studies and human ethics approval for human implants.
Pharmaxis drug earns FDA 'orphan' status for cystic fibrosis
20 July, 2005 by Helen SchullerThe US Food and Drug Administration has expanded an 'orphan drug' designation to Pharmaxis' (ASX:PXS) drug Bronchitol, for the additional indication of facilitating mucus clearance in patients with cystic fibrosis.
Peptech, Domantis in new cancer target development
20 July, 2005 by Graeme O'NeillSydney biotech Peptech (ASX:PTD) has signed up with its 36.1 per cent owned UK partner Domantis to develop a domain antibody (dAb) for the cancer target identified by its Sydney joint venture partner Biosceptre.
Narhex hires Polish groups for drug development
18 July, 2005 by Ruth BeranSydney anti-viral drug developer Narhex Life Sciences (ASX:NLS) has signed separate manufacturing research agreements with two Polish organisations to reduce the cost and complexity of manufacturing its HIV protease inhibitor DG-35.
Cantor: why biomarkers will change medicine
18 July, 2005 by Ruth BeranIn five years time, biomarker analysis will deliver inexpensive, reliable tests for disease prognosis, delegates at a joint BioMelbourne and Australian Genome Research Facility event heard last week.
First US implant for Ventracor
18 July, 2005 by Ruth BeranSydney-based Ventracor (ASX:VCR) has implanted its first VentrAssist left ventricular assist system (LVAS) in the United States.
GM canola found in Australian consignment to Japan
15 July, 2005 by Graeme O'NeillRoutine tests by the Australian Barley Board have detected traces of genetically modified canola seed in a small consignment canola to Japan, triggering a strong reaction from anti-GM activist organisations.
Columna to receive AUD$3.5 million in QBF funding
15 July, 2005 by Helen SchullerSpinal implant technology company Columna has secured AUD$3.5 million in funding from Queensland BioCapital Funds for the development of spinal orthopaedic implants.
Biocomm and Monash University collaborate to establish CNSBio
15 July, 2005 by Ruth BeranBusiness development and seed finance company Biocomm Services and Monash University, through Monash Commercial, have established CNSBio -- a new Melbourne-based company focused on the research and treatment of pain associated with cancer and chronic inflammatory diseases.
Rockeby granted US patent for candida detection kit
14 July, 2005 by Helen SchullerRockeby biomed (ASX:RBY) has been awarded an additional US patent over its SysCan3 Hospital Test Kit for use in the diagnosis of candida infections such as systemic candidiasis and thrush.
GroPep clarifies its recurrent miscarriage project to the market
14 July, 2005 by Ruth BeranMedia speculation has forced Adelaide-based GroPep (ASX:GRO) to clarify its position on ethics committee approval for a clinical study of an infertility drug.
Relenza inventor Mark von Itzstein wins Adrien Albert Award
14 July, 2005 by Ruth BeranProf Mark von Itzstein has won the RACI's Adrien Albert Award for his contribution to medicinal chemistry through the design and development of anti-influenza virus drug Relenza.
Novogen drug said to promote wound healing
11 July, 2005 by Ruth BeranA phase II trial conducted by Novogen (ASX:NRT) subsidiary Glycotex has found that its wound healing compound Glucoprime promotes healing in venous stasis ulcers.
